BioMed Valley Discoveries

Executive Summary

BioMed Valley Discoveries (BVD) is a clinical-stage biotechnology company based in Kansas City, Missouri, focused on translating novel science into breakthrough therapies for areas of high unmet medical need. Leveraging a unique, privately funded model that enables pursuit of higher-risk early-stage assets, BVD's pipeline includes programs in oncology and other serious diseases. The company's lead candidate, ulixertinib, is an ERK inhibitor in Phase 2 development for solid tumors, with the potential to address MAPK pathway-driven cancers. BVD's approach emphasizes scientific innovation and disciplined execution, positioning it to deliver meaningful therapeutics. While the company operates with less visibility than publicly traded peers, its stable funding and focused pipeline mitigate some development risks.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 data readout for ulixertinib in a solid tumor indication45% success
• Q4 2026Potential partnership or licensing deal for ulixertinib30% success